drugset / Trial / NCT07646860

A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)

NCT07646860

Phase 2 Not yet recruiting 6 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment. Researchers also want to learn what happens to it in a person's body over time and whether it lowers resistance in blood vessels in the lungs.

Timeline

Start
2026-08-31
Primary completion
2029-05-24
Completion
2031-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotatercept Protein / enzyme biologic 0.7 mg/kg Subcutaneous